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Abstract II 
Microtubules are being investigated as organic templates for 
nanowire fabrication. Targeted immobilization of the plus and minus 
ends of the microtubule can be achieved using recombinant end tracking 
microtubule proteins. This work examines the effects of five 
recombinant microtubule proteins on microtubule polymerization to 
determine their usefulness as inorganic surface ligands. GST-GAMMA-
tubulin was found to retain its microtubule nucleating capacity and 
anchor microtubules to an inorganic surface. GST-CLIP-170-H2, HIS-
CLIP-170-H2, GST-P150glued, and GST-EBl were all found to retain their 
microtubule binding capacity. GST-P150glued and GST-EBl were used to 
immobilize microtubules to inorganic surfaces. Their activity was 
enhanced by the presence of the H2 fragments. 
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Introduction III 
A. Microtubu1es As Nanowire Temp1ates 
In vivo, mictroubules are cellular structures found in the 
cytoplasm of eukaryotic cells. They are involved in many cellular 
processes including motility, cell division, and transport. 
Microtubules are protein filaments composed of tubulin subunits. Alpha 
and beta tubulin monomers associate with one another to form a 
heterodimer in solution. 
Each monomer is approximately 450 amino acids and has a molecular 
mass of 50,000Da (1). The tubulin heterodimer is about 8nm long and 
has a diameter of 4-Snm (2). Tubulin heterodimers stack end-to-end to 
form protofilaments. A microtubule is composed of a tube of thirteen 
protofilaments arranged into a helical lattice. Due to the structural 
differences between a and~ tubulin, microtubules are polarized 
structures with unique properties corresponding to each end. 
Microtubules are only 24 nanometers in diameter but can grow up 
to several microns in length. This relatively large geometric aspect 
ratio has made microtubules an attractive candidate for use as nanowire 
templates. Their ability to self-assemble from aqueous solutions of 
protein subunits by simply raising the temperature of the reaction 
vessel makes low-cost batch fabrication of entire circuits a 
possibility. A method for metallizing microtubules by electroless 
deposition has already been described, (2,3) and characterized by 
electron microscopy (4). Parallel assembly of complex circuits could 
be accomplished without any manual manipulation if adequate control 
over the targeting of nucleation and capture could be achieved. 
In vivo, the microtubule is accompanied by a vast array of 
microtubule-associated proteins (MAPs). These are proteins that 
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interact with both microtubules and each other to regulate microtubule 
polymerization, localization, and function. Complexes of these 
proteins are known to form structures called caps at the tips of 
microtubules. Caps prevent disassembly and participate in anchoring 
microtubules to other structures. The high specificity of these 
biological interactions can be utilized to achieve exquisite control 
over the fabrication process at the nanometer scale. 
Dividing cells are able to direct the polymerization of 
microtubules between centrosomes and kinetochores with near-perfect 
accuracy during anaphase. These structures represent target areas of 
about 0.5µm2 each. In vitro this search-and-capture strategy could be 
mimicked by exposing end-anchored microtubules to cycles of heating and 
cooling in solution of free tubulin dimer. This would induce growth 
and collapse of microtubules at random vectors from the anchoring site. 
Upon capture of the dynamic end, the microtubule would be stabilized 
and protected against depolymerization pending metallization. 
Surface adhesion complexes incorporating recombinant end-capping 
proteins would allow for the targeted anchoring of microtubule nanowire 
templates to metal electrodes. Recombinant versions of several end-
capping MAPs have already been engineered into plus and minus end 
specific surface adhesion complexes. Eventually, a library of 
recombinant proteins could provide enough multiplicity between paired 
target sites to construct complex circuits. 
B. Microtubu1e Polymerization 
The proximal end exposing a-tubulin has been termed the minus 
end. This is the end of the microtubule where nucleation occurs in 
vivo. The mechanisms and structures involved in microtubule nucleation 
are not completely understood at the present. 
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Consolidation of various models describing spontaneous homogenous 
nucleation, heterogenous microtubule nucleation, and microtubule 
dynamic instability into a unified theory of microtubule polymerization 
is an ongoing effort. The characterization of various microtubule 
associated proteins (MAPs), drugs, and other small molecules involved 
in nucleation has revealed an extremely complex system of signaling and 
regulation. This work focuses on qualitative evaluations of 
microtubule nucleation and polymerization dynamics. 
The distal end of the microtubule exposes a ~-tubulin subunit and 
has been termed the plus end. While both ends of the microtubule are 
capable of the addition and removal of tubulin heterodimers, the plus 
end is 5-10 times more dynamically active than the minus end (5). In 
vivo during eukaryotic cell division, the plus end is the site of 
microtubule capture and subsequent stabilization. Growth of astral 
microtubules is directed towards the kinetochore of dividing 
chromosomes. When the plus end of a mitotic microtubule properly 
encounters a kinetochore, it is anchored and capped preventing 
subsequent depolymerization. 
Each a and~ tubulin monomer binds to one molecule of guanosine 
triphosphate (GTP) to form Tu-GTP. The GTP bound to ~-tubulin is 
exchangeable, while the GTP bound to a- tubulin is non-exchangeable. 
The addition of a a/~ heterodimer to the end of a growing microtubule 
is effectively coupled to the hydrolysis of the ~-tubulin bound GTP. 
The resulting Tu-GDP is non-exchangeable. Hydrolysis of GTP changes 
the conformation of tubulin from curved to straight enhancing the 
lateral presentation of tubulin dimers to one another (6). 
Prior to hydrolysis, the region of the microtubule plus end 
comprising the unhydrolyzed layer of Tu-GTP is termed the cap. The 
details regarding its structure and mechanism are still quite unclear. 
8 
Presently, the predominant model describes a lateral cap composed of a 
single layer of Tu-GTP subunits. The hydrolysis of the exposed Tu-GTP 
to Tu-GDP is effectively coupled to the addition of a replacement Tu-
GTP dimer to the cap (7,8). The presence of this cap is thought to 
stabilize the microtubule and prevent its collapse. 
Hydrolysis of the plus end Tu-GTP taking place without the 
subsequent addition of a replacement heterodimer, presumably due to a 
lack of free Tu-GTP dimers in solution, results in a destabilization of 
the plus end of the microtubule. The resulting event is called 
catastrophe and represents a rapid and significant collapse of the 
microtubule from the distal end due to dissociation of uncapped Tu-GDP. 
When a catastrophe, or rapid disassembly event, is followed by a growth 
phase, this is called a rescue event. Presumable this results from the 
addition of a new layer of Tu-GTP and a replacement of the plus end 
cap. 
Dynamic instability is the term used to describe the exchange of 
free tubulin dimer with constitutive microtubule dimer via cycling 
between phases of slow growth or rescue, pausing, and catastrophe. The 
alternative process that describes the dynamic behavior of microtubules 
at a steady state length is treadmilling. This refers to the migration 
of individual tubulin subunits along the microtubule itself, from the 
distal plus end to the proximal minus end. This process can occur with 
both ends anchored and like dynamic instability, requires a constant 
supply of GTP (1). 
In the presence of GTP and heat, a/~ tubulin dimers will self-
assemble into microtubules, provided that the free dimer concentration 
is greater than the critical concentration. The critical concentration 
is the minimum concentration required for microtubule polymerization 
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and dynamic instability to occur. Under standard conditions and 
without the presence of drug the observed critical concentration of 
tubulin is .2mg/mL (l.8µM) (9,10). 
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This value is dynamic and can be raised or lowered in the 
presence of small molecules, drugs, and proteins that interact with 
microtubules to stabilize them and promote assembly or destabilize them 
and promote disassembly. These factors can alter the polymerization 
kinetics of the microtubules and/or affect the stability of already 
formed microtubules. Taxol (paclitaxel) is an example of a drug that 
stabilizes microtubules and promotes assembly by lowering the critical 
concentration (9). Taxol binds to polymerized microtubules at an 
exposed site on~- tubulin with a stoichiometry of 1:1 (11). The 
binding of taxol to microtubules induces conformational changes that 
prevent the catastrophe that would normally result from the loss of the 
plus end cap. In the presence of as little as SµM Taxol the critical 
concentration drops to ~O.Olmg/mL (9). In addition to altering the 
microtubule polymerization kinetics, Taxol can be used to stabilize 
preformed microtubules. A solution containing lOuM Taxol is capable of 
maintaining microtubules for up to a week. 
The effect of some MAPs on microtubule polymerization dynamics 
can be similar to that of a drug like Taxol, depending on what the 
normal function of the protein in question is. Changes in the critical 
concentration, dissociation rates, growth rates, length distributions, 
and other polymerization parameters of microtubules polymerized in 
solution can be used as markers to evaluate whether a recombinant MAP 
has retained its interaction with microtubules. 
Minus End Nucleation In Situ IV 
A. Microtubul.e Nucl.eation 
Microtubule nucleation is the process in which free tubulin 
dimers assemble and associate into a microtubule seed. This seed acts 
as a template for the addition and removal of polymerizing tubulin 
dimers. In vitro, nucleation will occur spontaneously in solutions of 
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free tubulin, provided that the concentrations of tubulin dimer and GTP 
are high enough. This happens at a rate that is dependent on the 
initial concentrations of GTP and tubulin. While the exact mechanism 
is unknown, the formation of two-dimensional sheets of tubulin has been 
well documented in solutions of purified tubulin (12). It is thought 
that these sheets fold into rings that act as nucleating seeds by 
forming templates for the addition of GTP bound tubulin heterodimers. 
In vivo nucleation occurs at microtubule organizing centers. 
During mitosis in dividing cells the centrosome acts as a microtubule 
organizing center (MTOC) to regulate nucleation. Large protein 
complexes called gamma tubulin ring complexes (y-TuRCs) are the site of 
nucleation. Gamma tubulin is a monomeric species of tubulin that is 
structurally similar to beta tubulin (13). It's presence is required 
for the nucleation of microtubules in vivo(6,13). 
The structure of gamma tubulin is such that in the unbound state 
it's conformation allows for lateral interactions between monomers(6). 
The formation of y-TuRCs is not a requisite for nucleation, however. 
Monomeric y-tubulin has been show to nucleate microtubule growth in 
vitro (13). As a monomer, y-tubulin lowers the size of the nucleus 
from seven to three tubulin subunits (13) by enhancing the 
intrinsically weak lateral interactions between dimers (6). Oligomers 
of y-tubulin in y-TuRCs act as a template for nucleation (14). The 
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binding of gamma tubulin to the minus end of a microtubule caps the 
minus end, preventing growth and polymerization (13,15). The 
nucleating mechanism of gamma tubulin as well as its exact interactions 
with microtubules and tubulin is still not completely understood (16). 
We have engineered a recombinant version of gamma tubulin that 
has been tagged with glutathione-S-transferase. This GST-y-tubulin 
will bind to a surface adhesion complex containing an antibody to GST. 
Microtubules nucleated from this GST-y-tubulin will therefore be 
anchored at their minus end, assuming that the recombinant protein is 
viable. In this work the nucleating capacity of GST-y-tubulin has been 
evaluated in solution with polymerizing microtubules and from surfaces 
functionalized with it as part of an adhesion complex. 
B. Effects of GST-y-Tubu1in In Situ 
The presence of nucleating seeds in solution has predictable 
effects on the polymerization dynamics of microtubules. Spontaneous 
nucleation of free tubulin dimer is slow without a nucleating agent. 
This implies a lag time between the initiation of polymerization and 
the appearance of microtubules of about 12 minutes under standard 
conditions (13). The addition of y-tubulin reduces this observed lag 
time in a dose dependent manner (13). 
When we polymerized purified tubulin in the presence of GST-y-
tubulin, long microtubules (>Sµm) were observed after 10 minutes (fig. 
1). Length distributions were obtained by measuring the microtubules 
from at least three different images per trial, and three different 
trials per treatment group. All of the counts for each treatment group 
were summed together. Images were selected to be representative 
samples of each group. 
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Figure 1 - (a) The three figures above show length 
distributions generated when 0.17mg/ml Purified 
Rhodamine-tubulin was polymerized at 37°C in PEM buffer 
(80mM Na-PIPES pH6.9, 1mM MgCl2, 1mM EGTA), 
0.21mM GTP, and 16.?uM Taxol alone (A) and with 
0.008mg/ml GST-y-Tubulin (B) for 10, 20, and 30 minutes. 
The presence of microtubules >Sµm after ten minutes in 
the GST-gamma-tubulin treated groups indicates an 
attenuation of the nucleation lag phase due to the 
nucleating effects of the recombinant protein. After 30 
minutes the GST-y-Tubulin groups contained longer 
microtubules. This supports a longer growth phase and 
minus end stabi lization brought on by the nucleating 
activity of the GST-gamma-tubulin construct. (b) The 
image to the right is an example of the images that were 
used to generate length distributions. 
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A stoichiometric evaluation of the solution conditions 
represented by figure one suggests that only a small fraction of the 
total GST-y-tubulin present is functioning as a minus end cap. The 
concentrations of tubulin dimer and GST-y-tubulin were l.7nM(0.17mg/mL) 
and 0.16nM respectively. Assuming that a microtubule is composed of 
thirteen tubulins arranged in a ring, this ratio corresponds to 
seventeen rows of tubulin dimer per nucleating cap of GST-y-tubulin. 
This also assumes that thirteen gamma tubulin are arranged into a minus 
end cap at a ratio of one gamma tubulin to each tubulin dimer. As we 
mentioned earlier, each tubulin dimer has a length of 8nm, with about 
1650 dimers constituting one micron of microtubule. If 100% of the 
GST-y-tubulin in solution was active as a nucleator and bound to the 
minus end of a microtubule, we would expect to see the microtubules 
grow to a maximum length of 0.136µm before depleting all of the free 
tubulin from the solution. The distribution we observed for these 
conditions indicated an average length closer to -Sµm. To reach these 
lengths with a 17:1 ratio of tubulin dimer to GST-y-tubulin, only about 
2.5% of the available GST-y-tubulin could have been bound to tubulin 
dimer. Such a low viability would probably be unacceptable for a 
surface ligand considering this statistic alone. Another explanation 
for this analysis is the presence of many undeveloped nucleation sites 
below the detection limit. These may consist of a ring of GST-y-
tubulin bound to a small number of tubulin dimers. Without affecting 
the length distribution, these nuclei could sequester most of the GST-
y-tubulin without significantly altering the free tubulin 
concentration. 
In a computer simulation of microtubule seeding where various 
amounts of preformed seeds were added to a polymerizing solution, the 
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Figure 2 - (a) The graph shown above represents a 
length distribution for 0.08mg/ml purified tubulin 
polymerized for 30 minutes at 37°C in PEM buffer 
(80mM Na-PIPES pH6.9, 1mM MgCl2, 1mM EGTA), 
0.21mM GTP, and 16.7uM Taxol alone (A) and with 
0.008mg/ml GST-y-Tubulin (B). The error bars 
represent the standard deviation of the average 
microtubule length between trails for each treatment 
group. The microtubules grew longer in the GST-
gamma-tubulin treated groups. This supports a 
shortening of the lag phase caused by the nucleating 
effect of GST-gamma-tubulin. The microtubules also 
reached longer lengths suggesting either a faster growth 
rate or a stabilizing effect. This would be consistent with 
the reported nucleating and elongating effects of 
unmodified gamma-tubulin on polymerizing microtubules 
in solution. A similar shift in the length distribution was 
also observed in computer simulations modeling the 
effects of seeding. (b) A size distribution of a simulated 
"seeding" experiment that shows the effect of adding a 
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1, 5, 10, or 20% weight concentration of microtubule 
seed to a slowly nucleating reversible microtubule 
system at a single fixed concentration of tubulin is 
shown to the right (ref. 17). Note the average length of 
~0.3µm increasing to about 0.4µm as more seed is 
added to the reaction solution . 
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Figure 3 - (a)The above graph represents a length 
distribution for 1.67mg/ml Purified tubulin polymerized for 
30 minutes at 37°C in PEM buffer (80mM Na-PIPES 
pH6.9, 1mM MgCl2, 1mM EGTA), 0.21mM GTP, and 
16.7uM Taxol alone (A) and with 0.008mg/mL GST-y-
Tubulin (B). The error bars represent the standard 
deviation of the average microtubule length between trails 
for each treatment group. When microtubules polymerized 
in higher concentrations of tubulin with GST-gamma-
tubulin a higher percentage of them were were short 
(between 0-Sµm) relative to the control groups. We 
suspect that this is the result of homogenous and 
heterogenous nucleation proceeding together in parallel to 
yield a large number of nuclei. The result of distributing 
the same amount of tubulin dimers amongst a larger 
number of microtubules is a shorter average length. This 
is consistent with the effects of unmodified wild type 
gamma-tubulin on polymerizing microtubules in solution. A 
similar shift in the length distribution was also observed in 
computer simulations modeling the effects of a fast 
nucleating growth environment. (b)The figure to the right 
shows a size distribution development of a rapidly 
nucleating reversible microtubule forming system (ref. 17). 
Note the average microtubule length is only about 0.1 µm in 
the fast nucleation scenario. 
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(*Figure from reference 17) 
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length distribution of the microtubules is skewed towards longer 
lengths (17) (fig 2). With enough nucleating seeds available the free 
GTP-Tu that is present in solution can be utilized to lengthen the 
preformed templates. This effect was reproduced with our recombinant 
GST-y-tubulin (Figs. 1 and 2) indicating that the recombinant gamma 
tubulin retains its nucleating capacity. 
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Figures 1 and 2 represent relatively low concentrations of free 
tubulin dimer (3.4nM and 1.6nM respectively) compared to the nucleating 
agent (GST-y-tubulin, 0.16nM). In this type of situation where there 
is a surplus of nucleating agent, new microtubules will arise 
exclusively from heterogenous nucelation. Compared to the control, 
which is exclusively homogenous nucleation, the GST-y-tubulin treated 
groups yielded longer microtubules. Figure 3 represents the length 
distribution of microtubules polymerized under similar conditions but 
from a higher initial concentration of tubulin dimer (34nM). When we 
polymerized microtubules in the presence of GST-y-tubulin at this 
higher tubulin concentration we observed shorter microtubules than in 
the control group. One possible explanation for this is that when 
enough tubulin is available, heterogenous and homogenous nucleation may 
occur simultaneously yielding a large number of shorter microtubules 
relative to a homogenously nucleating control group. This is 
consistent with predictions made by simulations of microtubule growth 
modeling fast nucleation conditions (17). It has also been shown that 
y-tubulin stabilizes tubulin oligomers by inhibiting GTP hydrolysis 
(13). More stable oligomers will result in less dissociation and 
subsequently lower free tubulin concentrations during polymerization. 
Also, y-tubulin has been shown to lower the critical concentration for 
microtubule nucleation. This would prolong the homogenous nucleation 
phase of microtubules in the GST-y-tubulin group, ultimately resulting 
in a greater number of shorter microtubules. 
18 
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Plus End Capture In Situ V 
A. P1us End Tracking MAPs 
The number of known MAPs has been increasing over the years as 
new proteins are identified. +TIPS are a subfamily of MAPs that are 
found localized to the plus end of growing microtubules. Within this 
group are proteins like APC and Tealp that are translocated to the plus 
end by a kinesis-based motility, and "plus-end-tracking" proteins that 
are thought to concentrate at the plus end of growing microtubules by 
copolymerizing with tubulin heterodimers (18). From the latter group 
we selected three proteins as plus-end anchoring candidates. 
Recombinant fragments of CLIP-170, EBl, and p15091ued were 
engineered previously and are evaluated here as potential components of 
the plus-end surface adhesion complex. Plus-end-tracking proteins do 
not preferentially bind microtubule ends in vitro (19). Instead they 
form co-complexes that copolymerize with tubulin heterodimers onto 
growing microtubule plus ends. 
B. Structure and Function of CLXP-170 
CLIP-170 is a 55kDa microtubule-organelle linker protein with two 
functional domains separated by a 950 amino acid stretch of heptad 
repeats (20). This region is a-helical in nature, and forms a 2-
stranded coiled coil that mediates dimerization of CLIP-170 in solution 
(20). The N-terminal domain binds to microtubules in vitro with a 
stoichiometry of one head domain to two tubulin heterodimers, or one 
dimer head domain to four tubulin heterodimers (19,20). This domain 
also has been found to be essential for binding microtubules in vivo 
(21). The C-terminal domain contains two predicted metal binding 
motifs and is involved in binding microtubules to peripheral 
cytoplasmic structures (21). Unbound CLIP-170 is auto-inhibited by the 
binding of its C-terminal domain to its N-terminal domain (19,22). 
plSOglued and EBl can relieve this inhibition by binding to the C-
terminal and N-terminal domains of CLIP-170 respectively (19,22). 
Activated CLIP-170 localizes to the plus end of growing microtubules 
(23) by preassociation with free GTP-Tubulin dimers and 
copolyrnerization, followed by rapid regulated release (24,25). 
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A pool of CLIP-170 is localized to the outer most region of 
unbound kinetochores, and to the plus end of elongating microtubules 
during mitosis, where it facilitates the formation of kinetochore-
microtubule attachements (26). CLIP-170 binds directly to the plSOglued 
subunit of the dynactin complex via the second metal binding motif of 
its C-terminal domain (27). This occurs in solution independently of 
the N-terminal microtubule binding domain (27). CLIP-170 also binds 
EBl via its N-terminal domain, forming a co-complex with tubulin 
heterodimer that copolyrnerizes into growing microtubules (19). 
EBl was found to be a requisite for plus end localization of 
CLIP-170 in mammalian cells (28). This could be due to the rapid 
dissociation of CLIP-170 from plus ends following copolyrnerization in 
the absence of EBl. In mutants lacking EBl, CLIP-170 dissociation from 
the plus ends of microtubules is accelerated (29). In mutants where 
EBl is overexpressed and distributed along the length of the 
microtubule, CLIP-170 continues to localize to the plus end but 
dissociates more slowly (29). 
For our purposes, two recombinant versions of the H2 fragment of 
CLIP-170 were generated for use as linkers between the surface adhesion 
complex and the growing plus ends of microtubules in our system. These 
constructs include both N-terrninal CAP-Gly binding domains and part of 
the heptad repeat chain, but do not include either of the C-terminal 
metal binding domains. The absence of the C-terminal binding domain in 
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our recombinant fragments precludes any direct binding of either of our 
CLIP-170-H2 constructs to either of the recombinant pl50gluect constructs 
that were evaluated. 
C. Effects of CLIP-170-H2 Constructs In Situ 
CLIP-170 is known to act as an anti-catastrophe factor to enhance 
polymerization of microtubules in vitro (18, 19, 26, 27). This work 
evaluates two evaluates two recombinant CLIP-170 fragments, GST-CLIP-
170-H2 and HIS-CLIP-170-H2. They are complexed with glutathione-S-
transferase(GST) and a short chain of amino acids, respectively. 
Overexpression of the microtubule binding domain of CLIP-170 in 
vivo results in bundling of microtubules (25, 27). Figures 4 and 5 
illustrate the bundling effect of the HIS-CLIP-170-H2 construct in 
solution. The H2 constructs appear to group the microtubules together 
and in some cases form aggregates. The large networks of bundled 
microtubules appear to be branched. This makes sense considering the 
role of CLIP-170 as a plus-end tracking protein. The formation of 
branches is consistent with bundling that is occurring at the 
polymerizing end of a microtubule. 
Figures 6 and 7 show the bundling effects of the GST-CLIP-170-H2 
construct. CLIP-170-H2 was shown to increase the proportion of 
outwardly curled protofilaments at the microtubule plus end (25). It 
is possible that these protofilaments play a role in the microtubule 
bundling effect that is observed in the presence of CLIP-170-H2. 
The H2 fragment of CLIP-170 induces the formation of tubulin 
rings in solution (25). Figure 4 demonstrates ring formation induced 
by the presence of the HIS-CLIP-170-H2 construct. These rings are 
absent in the GST conjugated construct, presumably due to the steric 
hinderance caused by the presence of GST. Glutathione-S-transferase is 
a 30kDa protein occupying significant space relative to the short chain 
of histidine residues present on the HIS-H2 construct. Similar 
findings were reported in other studies of recombinant H2 constructs 
(25) • 
The localization of CLIP-170 to Taxol stabilized microtubules is 
significantly reduced or abolished (27). The microtubules in figure 7 
were polymerized with higher concentrations of taxol and lower 
concentrations of tubulin than the microtubules in figure 6. This 
explains why the bundling appears to be more tightly clustered in 
figure 6 and the microtubules in figure 7 appear more elongated with 
less segmentation. 
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The morphology of the microtubules observed in these solutions is 
consistent with what we would expect from solutions containing high 
concentrations of H2. Taken together, these results confirm that a 
functional microtubule binding domain has been retained in these 
recombinant CLIP-170-H2 constructs. 
Figure 8 shows the length distribution of microtubules 
polymerized in the presence of GST-CLIP-170-H2. The microtubules 
polymerized in the solution containing the H2 fragment grew faster and 
reached longer lengths. This supports the conclusion that the 
recombinant H2 constructs have retained the ability to enhance 
polymerization. 
Control 
microtubules 
HIS-CLIP- l 70-H2 
treated microntbules 
Figure 4 - (a) Control microtubules polymerized from 1.67mg/ml purified 
tubulin polymerized for 30 minutes at 37°C in PEM buffer (80mM Na-PIPES 
pH6.9, 1mM MgCl2, 1mM EGTA), 0.21mM GTP, and 16.7uM Taxol are 
shown on the top. 0.008mg/ml HIS-CLIP-170-H2 is added to the reaction 
mixture prior to polymerization in the bottom figure (b). The red arrows 
indicate examples of ring formation that was induced by the HIS-CLIP-170-
H2 construct. These rings were not observed in solutions of microtubules 
polymerized with the GST-CLIP-170-H2 although extensive bundling was 
seen. We suspect this is due to steric interference from the relatively large 
S0kDa GST tag. 
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HIS-CLIP- l 70-H2 
treated microtubules 
Figure 5 - The images above illustrate the bundling of microtubules 
polymerized in solutions containing 1.67mg/mL purified tubulin 
polymerized for 30 minutes at 37°C in PEM buffer (80mM Na-PIPES 
pH6.9, 1mM MgCl2, 1mM EGTA), 0.21mM GTP, and 16.7uM Taxol 
with 0.008mg/mL HIS-CLIP-170-H2. The HIS-CLIP-170-H2 fragment 
induced the formation of (a ,d) microtubule clusters and (b,c) 
microtubule bundles . 
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GST-CLIP-l 70-H2 
Figure 6 - These pictures show branching and bundling of 
microtubules polymerized from solutions containing 1.67mg/ml 
Purified tubulin polymerized for 30 minutes at 37°C in PEM buffer 
(80mM Na-PIPES pH6.9, 1mM MgCl2, 1mM EGTA), 0.21mM GTP, 
and 16.7uM Taxol with 0.008mg/ml GST-CLIP-170-H2. Notice the 
GST-CLIP-170-H2 fragment mainly induced bundling (a), branching 
(b,c), and some dense clustering (d). Overall there was less 
aggregate formation relative to the HIS-H2 construct. 
HIS-CLIP-170-H2 
treated microtubules 
Figure 7 - These images are aggregates of microtubules from solutions 
containing 0.65mg/ml Purified tubulin polymerized for 30 minutes at 37°C in 
PEM buffer (80mM Na-PIPES pH6.9, 1 mM MgCl2, 1 mM EGTA), 0.21 mM 
GTP, and 33.4uM Taxol with 0.008mg/ml HIS-CLIP-170-H2. These 
solutions contained a lower initial concentration of tubulin dimer and higher 
concentrations of Taxol than was used in figures 6 and 7. The aggregates 
(a,b) appear to be less dense with less branching than those formed with 
the GST-H2 construct. This suggests that the presence of Taxol is 
interfering with the plus end activity of the H2 fragments. 
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Figure 8- The above graphs show length distribution for microtubules 
polymerized in solutions containing 0.17mg/ml purified tubulin 
polymerized at 37°C for 10 (a), 20 (b), and 30 (c) minutes in PEM buffer 
(80mM Na-PIPES pH6.9, 1mM MgCl2, 1mM EGTA), 0.21mM GTP, and 
16.?uM Taxol alone (A) and with 0.008mg/ml GST-CLIP-170-H2. The 
error bars represent standard deviation of the average microtubule 
length between trails for each treatment group. The presence of 
microtubules >Sµm after 10 minutes of polymerization in the GST-CLIP-
170-H2 treated groups indicates a slight nucleating effect. After 30 
minutes the GST-CLIP-170-H2 groups contained longer microtubules. 
This confirms published findings that CLIP-170-H2 acts to enhance 
polymerization. 
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D. Structure and Function of EBl and p150glued 
EBl is a 30kDa microtubule plus-end-tracking protein that binds 
CLIP- 170 (19), centrosomes, the tumor supressor protein adenomatous 
polyposis coli (APC), and pl5091 uect ( 30) . It contains an N-terminal CH 
domain that is involved in binding microtubules, and a C-terminal motif 
associated with APC and pl5091 uect binding (30) and centrosomal 
localization (31). pl5091uect is a lS0kDa dimeric protein that is 
involved in centrosomal anchoring (31) and transport (3 2 ). It binds 
dynein to form a minus end directed microtubule motor called the 
dynactin complex. 
EBl exhibits an auto-inhibiting structure in its unbound state 
similar to CLIP-170. The C-terminal domain binds to the N-terminal 
domain, sterically blocking access to the microtubule binding site of 
EBl. Binding of the C-terminal domain to pl5091 uect releases the N-
terminal domain allowing EBl to interact with microtubules (22). CLIP-
170 and pl5091 uect compete with each other for binding to the C-terminal 
domain of EBl (19). 
This competitive inhibition makes sense considering the 
differential role of these proteins during mitosis. An interaction 
between pl5091 uect and EBl is required for minus end anchoring of 
microtubules to the centrosome and is necessary for the elongation of a 
radial microtubule array from the centrosome to proceed (31). 
Elongating spindle microtubules incorporate CLIP-170 into their plus 
ends through a copolymerization mechanism. EBl binding to pl50
91
uect may 
act as both a checkpoint for minus end anchoring of microtubules and a 
signal initiating astral microtuble elongation by relieving the auto-
inhibitory function of EBl. Since the EBl/ pl5091uect interaction is 
independent of the microtubule binding domain, it is possible that 
cytoplasmic association of these two proteins facilitates their 
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colocalization to the minus end of nucleating microtubules. Once 
anchoring has taken place and EBl's minus end role has been fulfilled, 
CLIP-170 levels could replace p150gluect at the C-terminal through 
competitive binding and facilitate its transport to the plus end where 
it promotes elongation. Relief of CLIP-170 auto-inhibition may promote 
this transition by sequestering p150gluect following its release from EBl. 
Recall that CLIP-170 and p150gluect both naturally exist as dimers in 
solution, allowing them to complex with each other and EBl. As the 
microtubule lengthens, the co-complexes of these three proteins 
localize at the growing plus end where they facilitate kinetochore-
microtubule attachment and positioning. 
E. Effects of EBl and p15091ued Constructs In Situ 
EBl has been shown to exhibit promotion of microtubule rescue and 
inhibition of catastrophe resulting in enhanced elongation of 
microtubules (18, 19, 32, 33). Subsequent analysis of these findings 
suggests that the microtubule elongating effects of EBl may depend on 
the binding of APC or another activating protein (31, 32, 34). plSo~=ct 
has been shown to nucleate microtubules in vitro by lowering the 
critical concentration (33). A separate study reported conflicting 
results, claiming that p150gluect did not nucleate microtubule 
polymerization in the absence of seeds (22). The role of p150gluect as a 
regulator of microtubule polymerization in vitro remains unclear at the 
present. 
To evaluate this effect, length distributions for microtubules 
polymerized in vitro were obtained for low and high concentrations of 
recombinant EBl and p150gluect constructs (Figs 9 and 10 respectively). 
The recombinant proteins did not demonstrate a significant effect on 
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Figure 9 - This graphs shows length distributions for 0.33mg/mL(7µM) 
Purified tubulin polymerized for 30 minutes at 37°C in PEM buffer 
(80mM Na-PIPES pH6.9, 1mM MgCl2, 1mM EGTA), 0.21mM GTP, and 
16.?uM Taxol alone (A) and in combinations with 0.09mM GST-EB1 
(B) , 0.13mM p15091ueij (C), 0.33mM GST- p150910ed (0), 0.09mM GST-
EB1 + 0.13mM p15091ue<1 (E) , and 0.09mM GST-EB1 + 0.33mM GST-
p1 S091"ed (F). The error bars represent the standard deviation of the 
average microtubule length between tra ils for each treatment group. At 
this concentration there is no statistically significant effect on 
polymerization by the plus-end constructs. 
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Figure 10 - Length distribution for 0.33mg/mL(7µM) 
Purified tubulin polymerized for 30 minutes at 37°C in PEM 
buffer (80mM Na-PIPES pH6.9, 1mM MgCl2, 1mM EGTA), 
0.21mM GTP, and 16.7uM Taxol alone (A) and in 
combinations with 4.6mM EB1 (B), 1.3mM.J>1509Ju•d + 
4.6mM EB1 (C), and 3.3mM GST- p15091" + 4.6mM EB1 
(D). At higher concentrations relative to figure 9 there is 
still no statistically significant effect on polymerization by 
the plus-end constructs. The presence of Taxol in the 
reaction solution may inhibit plus-end tracking MAP 
activity, masking any growth effects caused by the capping 
protein constructs. 
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the length distributions of microtubules polymerized in their presence. 
The localization of both EBl and p150glued to Taxol stabilized 
microtubules was significantly reduced or abolished (27). The use of 
Taxol in generating these length distributions may explain why no 
significant elongation was observed in the treatment groups that 
combined the EBl and p150glued constructs. This may also explain the 
lack of apparent nucleation by the treatment groups containing p15091ued 
constructs alone. 
EBl and p150glued are known to induce microtubule bundling upon 
overexpression (33, 31). The bundled microtubules resulting from 
increased levels of EBl are longer than control, while microtubules 
polymerized with increased levels of p15091ued are shorter than control 
(33). The resulting bundles were shown to be very stable and resistant 
to the microtubule destabilizing agent nocodazol. 
Solutions of preformed rhodamine-tubulin microtubules were 
diluted in PEM buffer containing the EBl and GST-p150glued constructs and 
observed over the course of 10-15 minutes (figs 11 and 12). After 2-3 
minutes all of the microtubules in the solution had dissociated beyond 
a detectable limit. The EB1/p150glued constructs did not inhibit 
disassembly following the dilution as we had predicted. It is possible 
that the disassembly brought on by the dilution exceeded the capacity 
of the EB1/p150glued complex to inhibit catastrophe. Another possibility 
is a loss of functionality due to the lingering presence of Taxol in 
the dilution. The concentration of Taxol in the dilution solution was 
about lµM. 
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Figure 11 -A microtubule stock solution containing 7 µM tubulin was 
polymerized for 30 minutes at 37°C in PEM buffer (80mM Na PIPES 
pH6.9, 1mM MgCl2, 1mM EGTA). 0.23mM GTP, and 46µM Taxol. 
The microtubule stock solution was then diluted 1 :50 in PEM (A and 
B) and PEM containing 1.84mM EB1+1 .32mM GST-p15091" 0 d (C and 
D). Images were obtained 1,3,5, and 10 minutes following the 
dilution. The microtubules were mostly all gone after three minutes 
in the diluted solution. At ten minutes aggregates appeared in the 
solutions containing EB 1 and p150 but not in the control groups, 
suggesting that the recombinant protein fragments induce bundling 
and/or growth in solutions that are too dilute to otherwise support 
polymerization . 
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Figure 12 - 7 µM tubulin was polymerized for 30 minutes at 
37°C in PEM buffer (80mM Na PIPES pH6.9, 1 mM MgCl2, 1 mM 
EGTA). 0.23mM GTP, and 46µM Taxol to yield a microtubule 
stock solution. The stock solution was diluted 1: 50 in PEM (A) 
and PEM containing 0.92mM EB1+0.67mM GST-p15091"" d (8) 
and PEM containing 0.92mM EB1+0.67mM GST 
p15091ue<i+38µM HIS-CLIP-170-H2 (C). Images were then 
obtained at 1,5, 10, and 15 minutes after the dilution. At five 
minutes the microtubules had completely disappeared . Arrows 
indicate aggregates that appeared in the groups containing EB1 
and p150 but not in the control. The aggregates formed sooner 
when the CLIP-170-H2 fragment was in the dilution solution, 
suggesting that H2 may enhance the effect of EB1 and p150. 
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After a lag period of about 10 minutes from the initial dilution 
large aggregates of tubulin appeared in the groups containing 
recombinant proteins, but were absent from the control groups. This at 
least proves that the recombinant proteins have retained some ability 
to bind and bundle microtubules. It is possible that the rescuing 
properties of EBl and nucleating capacity of p15091ued also contributed 
to the formation of the observed aggregates. However, it is equally 
likely that no nucleation or growth occurred during the lag phase. 
Instead, disassembly could have shortened the microtubules to a length 
that was undetectable in the light microscope pending sufficient 
bundling into larger complexes. Interestingly, when HIS-CLIP-170-H2 
was added to the dilution buffer containing EBl and pl5091ued a reduction 
in the lag period preceding the appearance of the aggregates was 
observed (fig 12). 
Taken together, these results demonstrate that the recombinant 
plus-end-tracking protein constructs interact with microtubules in 
situ, significantly altering tubulin polymerization dynamics and 
microtubule morphology. The observed effects are consistent with the 
known properties of their unaltered wild type analogs. 
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Surface Immobilization VI 
A. SAM Compl.ex 
After confirming the capacity of the recombinant CLIP-170-H2 
constructs to bind and bundle microtubules, we used the H2 fragment 
that was conjugated to glutathione-S-transferase (GST) to evaluate the 
integrity of our surface adhesion complex. Figure 13 shows a sharp 
contrast in fluorescence between two SAM functionalized wafers 
following exposure to tubulin heterodimer and subsequent anti-tubulin 
immunolabeling. The lower wafer was exposed to O.OSmg/mL GST-CLIP-170-
H2 and the upper wafer was not. The bright fluorescence emitted by the 
lower wafer relative to the control wafer above it indicates that the 
anti-GST surface adhesion complex effectively bound the GST-CLIP-170-H2 
construct, which in turn bound the tubulin heterodimer and emitted 
fluorescence. This supports the retention of a viable microtubule 
binding domain in the H2 construct, confirms the association of 
conjugated glutathione-S-transferase to anti-GST antibody, and 
validates the presence of a working surface adhesion complex. Previous 
work confirmed these findings by binding a recombinant GST-y-tubulin 
construct to fluorescently labeled GFP-anti-y-tubulin antibody and 
verified the viability of each element in the surface adhesion complex 
using fluorescent microscopy (35). 
B. Microtubul.e Anchoring From Functional.ized Surfaces 
Gold plated silica wafers were functionalized with SAM of surface 
adhesion complexes (MHA) bound to anti-GST. These surfaces were 
exposed to either GST-y-tubulin or GST-p150glued and evaluated for their 
ability to immobilize microtubules at their ends. Fig. 14 shows 
control surfaces functionalized with the SAM but without the 
recombinant capping protein were exposed to polymerizing microtubules 
to compare with the GST-gamma-tubulin surfaces and pre-polymerized 
microtubules to compare with the plus-end-tracking surfaces. 
The GST-y-tubulin functionalized surfaces were exposed to the 
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tubulin solution during polymerization in order to allow for nucleation 
to take place from the surface bound y-tubulin constructs. 
100 l,lffl 
Figure 13 - Two gold plated silica surfaces functionalized with anti-GST bound 
surface adhesion complexes. The lower surface was exposed to 0.0Smg/ml 
GST-CLIP-170-H2 while the upper surface was not. Both surfaces were then 
incubated with tubulin heterodimer and immunolabeled with 1° antibody specific to 
13-tubulin Cy3 2° antibody antibody. The sharp contrast in fluorescence indicates 
successful binding of tubulin dimer to the functionalized surface. 
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Figure 15 shows a microtubule that is anchored to the SAM-y-tubulin 
functionalized surface by its minus end, while the distal plus end 
floats freely in solution. In comparison to the controls in figure 14, 
Figure 15 clearly indicates MT binding to the GST-y tubulin fusion 
protein. In figure 16 the microtubules indicated by the arrows are out 
of the surface plane of focus at one end. This corresponds to what 
would be expected from a microtubule that was anchored to the surface 
at one end and protruding outward normal to the surface of the wafer at 
the other end. 
Preformed microtubules were incubated with recombinant EBl during 
the last ten minutes of polymerization to ensure localization of the 
EBl construct to the dynamic plus end. These were then added to the 
GST-pl5091uect functionalized wafers to simulate a plus end capture 
scenario. Figure 17 shows the anchored plus end of the microtubule in 
focus at the left, the center region in focus in the middle, and the 
free minus end in focus well above the surface of the functionalized 
surface. Figure 18 shows other examples of microtubules that have been 
captured and immobilized to the surface at their plus end, while the 
minus end remains unbound and out of the plane of focus. Comparison 
with fig. 14c, shows clearly activity of the pl50-EB1 as a binding 
complex. Interestingly, Fig. 14d also shows MT binding to the pl50 
functionalize surface in the absence of EBl suggesting that EBl may not 
be necessary for plus end binding. 
The surfaces that were functionalized with GST-y-tubulin (figs 
15,16) appear to have significantly large amounts of background signal. 
This effect may be the result of small microtubule nuclei beyond the 
resolution limit of the microscope. As is the case with the formation 
of microtubule asters, nucleation of many microtubules from a 
stationary nucleation center results in a local depletion of free 
tubulin. The rate of diffusion of tubulin dimer in the solution 
governs the size of this depletion zone. The microtubules within this 
zone will undergo dynamic instability while competing with one another 
for free tubulin dimer. The competition between microtubules limits 
the amount of dimer 
Figure 14 - Images of control surfaces showing (a) an MHA functionalized 
surface submerged in microtubule stock solution (7µM tubulin + 10mM 
GTP + 2mM Taxol in PEM buffer) during polymerization, (b) an anti-GST 
functionalized surface submerged in microtubule stock solution (7µM 
tubulin + 1 0mM GTP + 2mM Taxol in PEM buffer) during polymerization , 
(c) an MHA functionalized surface submerged in pre-polymerized , EB1-
treated, microtubule stock solution (7µM tubulin + 10mM GTP + 2mM 
Taxol in PEM buffer heated to 37°C for 20 minutes before adding 
0.008mM EB1 and heating to 37°C for another 10 minutes), and (d) a 
p150 functionalized surface submerged in pre-polymerized microtubule 
stock solution (7µM tubulin + 1 0mM GTP + 2mM Taxol in PEM buffer). 
Controls (a), (b) and (c) show essentially no anchoring of MTs to the 
surface. Numerous MTs are anchored by one end to the surface in (d). 
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Figure 15 -A minus end microtubule is shown bound to a 
GST-gamma-tubulin functionalized Au surface. The image 
on the top (a) shows the anchored end in focus with an arrow 
pointing to the unbound end . The next two images (b,c) are 
focused at the unbound end and show it waving side to side 
in the solution. 
Figure 16 - The above images show three 
microtubules bound to a GST-gamma-tubulin 
functionalized gold surface. The anchored end is in 
the plane of focus in the image on the left (a). The 
unbound plus end is show in focus in the image on 
the right (b) while the other end is out of focus. 
This implies that microtubule is positioned 
perpendicular to the surface plane. 
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Figure 17 - This series shows three focal planes of an EB1 
bound microtubule anchored to a p150 functionalized surface. 
The anchored plus end is indicated by the arrow while the plus 
end (a), middle (b) , and unbound minus end (c) are in the focal 
plane. ••The above the image series at the top of the page is 
an image of a blank control surface for comparison . 
Figure 18 - Arrow in the images above point to 
three different EB 1 bound microtubules captured 
onto p150 functionalized surfaces. The arrow 
indicates the anchored end while the opposite end 
is unbound and out of focus. 
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available for growth resulting in high rates of catastrophe relative to 
elongation. Microtubules growing past the depletion zone will escape 
this catastrophe cycle. The dimer concentration outside the depletion 
zone is high, so escaping microtubules will generally grow very long 
relative to solution microtubules polymerized in similar conditions. 
This is a growth phenomenon and is therefore absent in the p150gluect 
capturing surfaces. 
Conclusions VII 
We have analyzed the nucleating capacity of GST-y-tubulin using 
length distributions of microtubules polymerized in solution. At low 
initial tubulin concentrations, GST-y-tubulin eliminated the lag phase 
corresponding to homogenous nucleation. It also enhanced the growth 
phase, yielding longer microtubules. This is consistent with 
simulations of microtubule polymerization in the presence of a large 
proportion of nucleating seeds relative to tubulin dimer. At high 
initial tubulin concentrations, GST-y-tubulin treated groups yielded 
many short microtubules. This is consistent with simulations and 
observations of solutions containing a surplus of tubulin and a fast 
nucleating agent. Taken together, these findings suggest that the 
recombinant GST-y-tubulin construct is functional as a microtubule 
nucleating agent and as an inorganic surface ligand. 
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We examined the effects of HIS-CLIP-170-H2 and GST-CLIP-170-H2 on 
microtubule polymerization in situ. Both of the recombinant CLIP-170-
H2 constructs that were evaluated demonstrated significant bundling at 
high concentrations in solution. The histidine tagged construct 
induced ring formation in solution while the GST bound construct did 
not. This is likely due to steric hinderance caused by the relatively 
large size of the GST domain. While both constructs appear to have 
retained their interaction with microtubules, HIS-CLIP-170-H2 does not 
appear to be impaired structurally like GST-CLIP-170. In solutions of 
diluted microtubules, the EBl and p150 constructs demonstrated 
aggregate formation following depolymerization. This bundling effect 
implies an ability to bind microtubules, which was enhanced by the 
presence of the HIS-CLIP-170-H2 construct. We conclude that all of the 
recombinant plus end tracking proteins have retained their ability to 
bind microtubules and are therefore suitable for use as inorganic 
surface ligands. 
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GST-y-tubulin and GST-p150 with or without EBl were shown to be 
able to anchor microtubules to functionalized gold surfaces, supporting 
our conclusion that these recombinant end-capping proteins are 
effective inorganic surface ligands. 
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APPENDIX A - Materials and Methods VIII 
Preparing GTP Aliquots (lOmM GTP in Water): 
1. Pipet lmL H20 into tube of lyophilized GTP powder and vortex to 
mix. 
2. Prepare lOµL aliquots in labeled tubes and store at -20°e. 
Preparing Taxol Aliquots (2mM Paclitaxel in DMSO): 
1. Resuspend lyophilized powder in lOOµL DMSO and vortex to mix. 
2. Prepare lOµL aliquots in labeled tubes and store at -20°e. 
Preparing Tubulin Aliquots (lOmg/mL Tubulin in PEM buffer): 
1. Prepare liquid nitrogen bath 
2. Resuspend lyophilized powder in lOOµL PEM buffer and pipet to 
mix. 
3. Prepare lOµL aliquots in labeled tubes. 
4. Snap freeze tubes by dropping them in liquid nitrogen while 
wearing proper protective gloves. 
5. Retrieve aliquots using forceps and store at -B0°e. 
Preparing Primary Antibody Aliquots (200µg/mL mouse a-p-tubulin in 10% 
glycerol): 
1. Prepare liquid nitrogen bath. 
2. Pipet lOOµL glycerol into 900µL H20 to make 10% glycerol. 
3. Resuspend lyophilized powder in 500µL 10% glycerol and pipet to 
mix. 
4. Prepare 5µL aliquots in labeled tubes 
6. Snap freeze tubes by dropping them in liquid nitrogen while 
wearing proper protective gloves. 
5. Retrieve aliquots using forceps and store at -B0°e. 
Preparing Secondary Antibody Aliquots (750µg/mL goat anti-mouse ey3 in 
50% glycerol): 
1. Pipet 1.lmL H20 into tube of freeze-dried power. 
2. Pipet 1.lmL glycerol into tube and pipet to mix. 
3. Prepare lOµL aliquots in labeled tubes and store covered at -
20°e. 
Determining Protein Concentrations: 
1. Turn on Nanodrop ND-1000 spectrophotometer. 
2. Select Protein A280 mode. 
3. Calibrate and blank spectrophotometer. 
4. Absorbance reading yields protein concentration in mg/mL. 
Microtubule Stock Solution (l.67mg/mL(33.4µM) Tubulin, 17µM Taxol, 
0.21mM GTP in PEM buffer): 
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1. Prepare an ice bucket and supply it with PEM buffer, GTP, Taxol, 
and tubulin. 
2. Place an open microcentrifuge tube that has been properly 
labeled in the ice bath. 
3. Pipet 48.25µL PEM buffer into the microcentrifuge tube. 
4. Pipet 1.25µL GTP (l0mM stock solution) into the microcentrifuge 
tube. 
5. Pipet 0.5µL Taxol (2mM stock solution) into the microcentrifuge 
tube by removing the tube from the ice bath and holding it up to 
a light background during pipeting. This is to ensure the 
delivery of such a small volume. An oily streak should be 
ejected from the pipet tip. 
6. Cap the tube and vortex to mix. 
7. Place the tube back in the ice bath and add l0µL tubulin 
(l0mg/mL). 
8. Pipet mix with 200µL pipet. 
9. Place the tube in a 37°C incubator for 30 minutes. 
*For a different concentration of tubulin or additional reagents 
change the amount of PEM buffer to maintain a final volume of 60µL 
Blocking Solution (2%BSA in PEM buffer): 
1. Weigh lg BSA into 250mL Erlenmeyer flask. 
2. Add l00mL PEM buffer to flask. 
3. Place stir-bar in flask and set stir plate to high for 10 
minutes. 
PEMTAX Solution (20mM Taxol): 
1. Place a labeled tube on ice. 
2. Pipet l000µL PEM buffer into labeled tube. 
3. Pipet l0µL Taxol (2mM stock) into tube. 
4. Vortex to mix and place on ice. 
Primary Antibody So1ution (l0µg/mL mouse anti-~-tubulin in blocking 
solution): 
1. Pipet l000µL blocking solution into labeled tube. 
2. Pipet SµL mouse anti-~-tubulin (2mg/mL stock). 
3. Vortex to mix and place on ice. 
Secondary Antibody So1ution (30µg/mL goat-a-mouse Cy3 in blocking 
solution): 
*ensure that the Cy3 remains covered at all times as it is light 
sensitive 
1. Pipet S00µL blocking solution into labeled tube. 
2. Pipet l0µL goat-a-mouse Cy3 (1.Smg/mL stock). 
3. Vortex to mix, cover with foil, and place on ice. 
Inmuno1abe1ing: 
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1. Prepare an ice bucket and supply it with PEM buffer, taxol, BSA, 
primary antibody (anti-~-tubulin), and secondary antibody (Cy3) 
2. Prepare l00mL blocking solution. 
3. Prepare lmL PEMTAX solution. 
4. Prepare a container of methanol large enough to fit a slide and 
place at -20°C. 
4. Prepare a 1:50 dilution of microtubule stock solution in PEMTAX. 
5. Label a poly-L-lysine coated slide and place it in a humid 
environment (i.e. A slide box containing wet paper towels). 
6. Pipet 200µL microtubule dilution onto PLL surface. Close the 
box securely and set at room temperature for 20 minutes. 
7. Prepare primary antibody solution. 
8. Prepare secondary antibody solution and keep covered on ice. 
9. Remove slide from humidity chamber after 20 minutes and rinse in 
PEM buffer by submerging completely in buffer ten times. 
*If staining multiple treatment groups prepare a separate wash for 
each slide to prevent cross contamination. 
10. Submerge slide ten times in -20°C methanol bath, then three 
times in PEM buffer. 
11. Place slide in blocking solution for 20 minutes at room 
temperature. 
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12. Remove slide from blocking solution and gently shake off excess 
blocking solution. 
13. Dry the sides and bottom of the slide on a small stack of paper 
towels taking care not to touch the PLL surface. Then place it 
back in the humid chamber. 
14. Pipet l000µL primary antibody solution onto the slide, close the 
slide box tightly, and set it at room temperature for 30 
minutes. 
15. Gently shake off excess primary antibody solution and rinse in 
blocking solution for 10 seconds. 
16. Dry the sides and bottom of the slide again on a small stack of 
paper towels. Then place it back in the humid chamber. 
17. Pipet l000µL secondary antibody solution onto the slide, close 
the slide box tightly, and set it at room temperature for 2 
hours. 
18. Gently shake off excess primary antibody solution and rinse in 
blocking solution for 10 seconds. 
19. Rinse in fresh PEM buffer and add a cover slip. The slide is 
now ready for fluorescent imaging. 
Imaging On The Fluorescent Microscope: 
1. Reserve microscope ahead of time. 
2. Log into sign-in sheet and turn on fluorescent lamp and 
computer. 
3. Ensure all shudders are open and set filter to emit 552nm light 
(usually green), then close the fluorescent light shudder. 
4. Open image acquisition software 
5. Set the objective to l00X. 
6. Ensure scale-bars are present at proper scale, set fluorescence 
to manual or automatic, depending on the experiment, and adjust 
other image acquisition parameters to fit experiment. 
7. Place one drop of objective oil directly on l00X objective. 
8. Route the image to the eyepiece, open the fluorescent light 
shudder, and obtain the desired image. 
9. Route the image to the computer and acquire the image using the 
software. 
10. Repeat 7 through 10 until finished, then save the images, turn 
off the lamp and computer, and sign-out. 
48 
Microtubu1e Dissociation (Aggregate Formation) Experiment: 
1. Prepare an ice bucket and supply it with PEM buffer, GTP, Taxol, 
tubulin, EBl, and pl50glued. 
2. Place an open microcentrifuge tube that has been labeled 
microtubule stock solution in the ice bath. 
3. Pipet 160µL PEM buffer into the microcentrifuge tube. 
4. Pipet 4µL GTP (l0rnM stock solution) into the microcentrifuge 
tube. 
5. Pipet 4µL Taxol (2rnM stock solution) into the microcentrifuge 
tube by removing the tube from the ice bath and holding it up to 
a light background during pipeting. This is to ensure the 
delivery of such a small volume. An oily streak should be 
ejected from the pipet tip. 
6. Cap the tube and vortex to mix. 
7. Place the tube back in the ice bath and add 6µL tubulin 
(l0mg/mL). 
8. Pipet mix with 200µL pipet. 
9. Place the tube in a 37°C incubator for 30 minutes. 
10. Pipet 490µL PEM buffer into tube labeled as control. 
11. Pipet 450µL PEM buffer into tube labeled as treatment. 
12. Pipet 20µL EBl into treatment group tube. 
13. Pipet 20µL pl5091uect into treatment group tube and pipet mix. 
14. After 30 minutes place all three tubes in the ice bath and move 
to the scope. 
15. Begin timer upon adding l0µL microtubule stock solution to each 
dilution tube. 
16. At the desired time points flick the dilution tube gently to mix 
the solution and pipet l0µL onto a poly-L-lysine coated 
microscope slide. 
17. Add a cover slip and image each time point. 
Surface Contrast (SAM Validation) Experiment: 
1. Obtain 2 anti-GST functionalized surfaces. 
2. Rinse in PBS. 
3. Pipet l0µL GST-CLIP-170-H2 onto one surface and leave at room 
temperature for 20 minutes. 
4. Rinse in PBS. 
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5. Pipet l0µL microtubule stock solution onto both chips and set at 
room temperature for 20 minutes. 
6. Prepare Block solution 
7. Prepare primary antibody solution 
8. Prepare secondary antibody solution 
9. Place both chips in block solution at room temperature for 20 
minutes. 
10. Place both chips in primary antibody solution for 30 minutes. 
11. Rinse both chips in block solution. 
12. Place both chips in secondary antibody solution for 1 hour. 
13. Rinse in PBS. Chips are now ready for imaging. 
Preparing SAM Functionalized Gold Surfaces: 
1. Obtain a silica wafer. 
2. Coat with a thin layer of chromium using physical vapor 
deposition. 
3. Deposit a ~l00nm layer of gold using physical vapor deposition. 
4. Clean the surface with Piranha solution (1:3 30% hydrogen 
peroxide: 95% sulfuric acid). This will partially oxidize the 
gold to Au+. 
5. Rinse the chip in water. 
6. Submerge chip in lrnM mercaptohexadonic acid in 10% ethanol for 
24 hours. 
Preparing BPT Solution: 
1. Pipet l0rnL PEM80 into centrifuge tube. 
2. Add 100mg BSA to tube. 
3. Pipet l00µL Taxol into tube and vortex thoroughly to mix, then 
set on ice. 
Nucleating Microtubules From Surface Using Regular Tubulin: 
1. Remove a chip from the MHA solution and rinse it with purified 
water. 
2. Place the chip on a clean surface approximately 10 inches from 
the lab bench air line and turn the air stream on low flow to 
air dry the chip. 
3. Prepare a hum.id environment by placing wet paper towels in a 
slide box. 
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4. Submerge chip in lmg/mL anti-GST + EDC in PEM buffer inside the 
slide box, close the lid tightly, and set at room temperature 
for 3-4 hours. 
5. Rinse chip in 2%BSA in PEM buffer for 20 minutes at room 
temperature. 
6. Inside the slide box pipet enough 0.05mg/mL GST-y-tubulin to 
cover the entire surface, close the lid tightly, and set for 30 
minutes at room temperature. 
7. Rinse chip in 2%BSA in PEM buffer for 5 minutes at room 
temperature. 
8. Prepare an ice bucket and supply it with PEM buffer, GTP, Taxol, 
and tubulin. 
9. Place an open microcentrifuge tube that has been labeled into 
the ice bath. 
10. Pipet 160µL PEM buffer into the microcentrifuge tube. 
11. Pipet 4µL GTP (l0mM stock solution) into the microcentrifuge 
tube. 
12. Pipet 4µL Taxol (2mM stock solution) into the microcentrifuge 
tube by removing the tube from the ice bath and holding it up to 
a light background during pipeting. This is to ensure the 
delivery of such a small volume. An oily streak should be 
ejected from the pipet tip. 
13. Cap the tube and vortex to mix. 
14. Place the tube back in the ice bath and add 6µL tubulin 
(l0mg/mL). 
15. Pipet mix with 200µL pipet. 
16. Carefully place the chip in the tube making sure not to touch 
the surface. 
17. Place the tube in a 37°C incubator for 30 minutes. 
18. Prepare a bath of -20°C methanol large enough to accommodate a 
microscope slide. 
19. Prepare blocking solution and keep on ice. 
20. Prepare regular primary antibody solution and keep on ice. 
21. Prepare regular secondary antibody solution and keep covered on 
ice. 
22. Prepare BPT solution and keep on ice. 
23. Pipet lmL BPT into tube labeled primary antibody in BPT 
solution. 
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24. Pipet 5µL primary antibody into primary antibody in BPT tube and 
keep on ice. 
25. Pipet 500µL BPT into tube labeled secondary antibody in BPT 
solution. 
26. Pipet l0µL secondary antibody into secondary antibody in BPT 
tube and keep covered on ice. 
27. Remove the tube containing the chip from the incubator and pipet 
l0µL of the microtubule solution onto a poly-L-lysine coated 
microscope slide labeled control. 
28. Set the slide at room temperature for 10 minutes. 
29. Carefully remove the chip from the tube and place into BPT rinse 
for 30 minutes at room temperature. 
30. Submerge slide ten times in -20°C methanol bath, then three 
times in PEM buffer. 
31. Place slide in blocking solution for 20 minutes at room 
temperature. 
32. Submerge the chip in primary antibody in BPT solution for 30 
minutes. 
33. Remove slide from blocking solution and gently shake off excess 
blocking solution. 
34. Dry the sides and bottom of the slide on a small stack of paper 
towels taking care not to touch the PLL surface. Then place it 
back in the humid chamber. 
35. Pipet l000µL primary antibody solution onto the slide, close the 
slide box tightly, and set it at room temperature for 30 
minutes. 
36. Rinse the chip in BPT. 
37. Place the chip in secondary antibody in BPT solution for 2 hours 
at room temperature. 
38. Gently shake excess primary antibody solution off the slide and 
rinse it in blocking solution for 10 seconds. 
39. Dry the sides and bottom of the slide again on a small stack of 
paper towels. Then place it back in the humid chamber. 
40. Pipet l000µL secondary antibody solution onto the slide, close 
the slide box tightly, and set it at room temperature for 2 
hours. 
41. Gently shake excess secondary antibody solution off the slide 
and rinse it in blocking solution for 10 seconds. 
42. Rinse the slide in fresh PEM buffer and add a cover slip. 
43. Place the chip in BPT solution. The functionalized chip and 
control slide are now ready to be imaged with a fluorescent 
microscope. 
Capturing Microtubu1es Onto Surface Using Regul.ar Tubul.in: 
1. Remove a chip from the MHA solution and rinse it with purified 
water. 
2. Place the chip on a clean surface approximately 10 inches from 
the lab bench air line and turn the air stream on low flow to 
air dry the chip. 
3. Prepare a humid environment by placing wet paper towels in a 
slide box. 
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4. Submerge chip in lmg/mL anti-GST + EDC in PEM buffer inside the 
slide box, close the lid tightly, and set at room temperature 
for 3-4 hours. 
5. Rinse chip in 2%BSA in PEM buffer for 20 minutes at room 
temperature. 
6. Inside the slide box pipet enough 5.91mg/mL GST-pl50glued to cover 
the entire surface, close the lid tightly, and set for 30 
minutes at room temperature. 
7. Prepare an ice bucket and supply it with PEM buffer, GTP, Taxol, 
and tubulin. 
8. Place an open microcentrifuge tube that has been labeled into 
the ice bath. 
9. Pipet 140µL PEM buffer into the microcentrifuge tube. 
10. Pipet 4µL GTP (l0mM stock solution) into the microcentrifuge 
tube. 
11. Pipet 4µL Taxol (2mM stock solution) into the microcentrifuge 
tube by removing the tube from the ice bath and holding it up to 
a light background during pipeting. This is to ensure the 
delivery of such a small volume. An oily streak should be 
ejected from the pipet tip. 
12. Cap the tube and vortex to mix. 
13. Place the tube back in the ice bath and add 6µL tubulin 
(l0mg/mL). 
14. Pipet mix with 200µL pipet. 
15. Place the tube in a 37°C incubator for 15 minutes. 
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16. Pipet l0µL 1.30mg/mL EBl and l0µL 0.lmg/mL HIS-CLIP-170-H2 into 
the tube. 
17. Pipet mix with 200µL pipet and place back in the incubator for 
15 minutes. 
18. Prepare a bath of -20°C methanol large enough to accommodate a 
microscope slide. 
19. Prepare blocking solution and keep on ice. 
20. Prepare regular primary antibody solution and keep on ice. 
21. Prepare regular secondary antibody solution and keep covered on 
ice. 
22. Prepare BPT solution and keep on ice. 
23. Pipet lmL BPT into tube labeled primary antibody in BPT 
solution. 
24. Pipet 5µL primary antibody into primary antibody in BPT tube and 
keep on ice. 
25. Pipet 500µL BPT into tube labeled secondary antibody in BPT 
solution. 
26. Pipet l0µL secondary antibody into secondary antibody in BPT 
tube and keep covered on ice. 
27. Remove the tube containing the microtubule stock solution from 
the incubator and pipet l0µL of the microtubule solution onto a 
poly-L-lysine coated microscope slide labeled control. 
28. Set the slide at room temperature for 10 minutes. 
29. Submerge slide ten times in -20°C methanol bath, then three 
times in PEM buffer. 
30. Place slide in blocking solution for 20 minutes at room 
temperature. 
31. Rinse the chip in 2%BSA in PEM buffer for 5 minutes at room 
temperature. 
32. Pipet 288µL BPT into a tube labeled microtubule dilution. 
33. Pipet 12µL microtubule stock solution into tube labeled 
microtubule dilution and pipet mix. 
34. Carefully place the chip in the microtubule dilution tube making 
sure not to touch the surface, close the lid, and place at room 
temperature for 30 minutes. 
35. Place the chip into BPT rinse for 30 minutes at room 
temperature. 
36. Submerge the chip in primary antibody in BPT solution for 30 
minutes. 
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37. Remove slide from blocking solution and gently shake off excess 
blocking solution. 
38. Dry the sides and bottom of the slide on a small stack of paper 
towels taking care not to touch the PLL surface. Then place it 
back in the humid chamber. 
39. Pipet l000µL primary antibody solution onto the slide, close the 
slide box tightly, and set it at room temperature for 30 
minutes. 
40. Rinse the chip in BPT. 
41. Place the chip in secondary antibody in BPT solution for 2 hours 
at room temperature. 
42. Gently shake excess primary antibody solution off the slide and 
rinse it in blocking solution for 10 seconds. 
43. Dry the sides and bottom of the slide again on a small stack of 
paper towels. Then place it back in the humid chamber. 
44. Pipet l000µL secondary antibody solution onto the slide, close 
the slide box tightly, and set it at room temperature for 2 
hours. 
45. Gently shake excess secondary antibody solution off the slide 
and rinse it in blocking solution for 10 seconds. 
46. Rinse the slide in fresh PEM buffer and add a cover slip. 
47. Place the chip in BPT solution. The functionalized chip and 
control slide are now ready to be imaged with a fluorescent 
microscope. 
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